A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre, dose escalation study to characterize the safety and
preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects
with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with
relapsed/refractory multiple myeloma in combination with standard therapy.